Truth in HempTM News Room
The need for safe, high-quality, truthful cannabinoid products has never been greater. Through science, quality, innovation, and scale, Folium Biosciences is unlocking the full potential of hemp and is committed to delivering highly refined 0.0% THC Broad Spectrum Oil with transparency, excellence, and expertise you won’t find anywhere else in the market. Folium Biosciences is often asked to contribute to various media outlets and answer questions about CBD and the world industrial hemp. As part of our commitment to always deliver the Truth in HempTM, we are pleased to share the latest resources, information, and company news needed to stay updated on our marketplace.
Have questions or want to help share the Truth in HempTM?
Get in touch! Email us at firstname.lastname@example.org. We can’t wait to chat.
Deciding which industrial hemp cannabinoid manufacturer to partner with is one of the most significant decisions that a business owner of a hemp consumer brand will ever make. From the top down, each decision that hemp cannabinoid manufacturers and suppliers make will...
J. Randal Wexler of FutureCeuticals/Van Drunen Farms and Former Nature’s Bounty Exec Mitchell Slade Join Folium Biosciences Advisory Board
Colorado Springs, Colo. – November 24, 2020 – Hemp-derived non-psychoactive cannabinoid manufacturer Folium Biosciences welcomes J. Randal Wexler, Vice President and General Counsel of FutureCeuticals/Van Drunen Farms, and Nature’s Bounty Co. veteran Mitchell Slade to...
One Year After Securing API License for Pharma Grade CBD, Folium Biosciences Reports Broad Global Pharmaceutical Adoption
Folium’s CBD API is an essential ingredient in pharmaceutical formulations worldwide. Colorado Springs, Colo. – October 15, 2020 – Since securing its Active Pharmaceutical Ingredient (API) license one year ago, Folium Biosciences’ CBD Isolate has been widely adopted...
Global Veteran Specialty Ingredient Sales Executive Kris High Joins Folium Biosciences as Chief Commercialization Officer
After two decades of global sales leadership in the specialty food and ingredient sectors, Kris High has joined the executive team at hemp-derived non-psychoactive cannabinoid manufacturer Folium Biosciences as the company’s first Chief Commercialization Officer
Folium Biosciences Introduces Broad Spectrum Stalk CBD Oil to Meet Global Demand from Stalk-and-Seed Countries Stalk-and-Seed Formulation Secures Approval for Distribution in Japan and South Korea. Folium Biosciences introduces Broad Spectrum Stalk...
Tricia DiPersio, PhD, RD, Joins Folium Biosciences as EVP of Quality, Compliance & Customer Relations
Food, beverage and supplements industry veteran Tricia DiPersio, PhD, RD, has joined the executive team at Folium Biosciences as the company’s first EVP of Quality, Compliance and Customer Relations.
Colorado Springs, Colo. – September 9, 2020 – Hemp-derived, non-psychoactive cannabinoid manufacturer Folium Biosciences welcomes Kandy Anand, former Chief Growth Officer at Molson Coors Brewing Company (NYSE: TAP), to its Board of Directors. “Advancing our company...
Folium Biosciences Names Nutralliance a Preferred U.S. Distributor of Company’s Hemp-Derived Non-Psychoactive Cannabinoid (CBD) Products
Hemp-derived non-psychoactive cannabinoid manufacturer Folium Biosciences and premium-ingredient sales and marketing company Nutralliance have entered a distribution partnership that grants Nutralliance the right to distribute Folium’s industry-leading 0.0% THC broad spectrum CBD oil products in the United States, and establishes Folium as Nutralliance’s exclusive CBD supplier.
Folium Biosciences Completes Construction of One of the World’s Largest Cannabinoid Extraction and Purification Facilities in Pueblo West, CO
Folium Biosciences has completed buildout and received a Certificate of Occupancy for the world’s largest cannabinoid extraction and purification facility, located in Pueblo West, Colo.
The new 110,000-square-foot Pueblo West facility will produce up to 22,000 kg of 0.0% THC broad spectrum CBD oil each month. To satisfy accelerating demand from CBD product manufacturers worldwide, the plant has dedicated production lines to meet CBD regulatory requirements in the US, EU, Japan, and South Korea, among other countries.
FDA registered and state-of-the-art, the new Folium facility is purpose-built for extraction, purification and formulation of cannabinoids and terpenes. The plant will utilize supercritical carbon dioxide (sCO2) extraction technology exclusively to produce phytocannabinoid-rich 0.0% THC broad spectrum CBD oil, adhering to a continuous process from decarboxylation to extraction that allows for a revolutionary inline terpene capture system.
The FDA is taking its first step in setting new regulations for cannabis Friday, holding a public hearing to dive into what its regulatory strategy should address. FDA Commissioner Scott Gottlieb has expressed concerns about companies making claims of the health benefits of CBD. But he also recognizes regulations are needed to provide clarity for companies that want to market cannabis products. Potential safety issues are expected to be a major topic at the hearing. (Fox Business)